M&A activity in the pharmaceutical industry in Singapore increased in 2023
In value terms, M&A activity in Singapore increased by 786% in Q2 2023 compared with the previous quarter’s total of $6.6m and fell by 83% as compared to Q2 2022. Related deal volume increased by 100% in Q2 2023 versus the previous quarter and was 300% higher than in Q2 2022.
For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
Source link
#activity #pharmaceutical #industry #Singapore #increased
